A Call For Better Monitoring and Treatment Of Scleroderma Patients PDF Print E-mail
Sunday, 01 July 2012 22:42
The New Zealand Scleroderma Group is calling for the introduction of a monitoring and treatment programme for New Zealanders with scleroderma to mark World Scleroderma Day on June 29.

Scleroderma is an autoimmune connective tissue disease that can affect many organs of the body. It is associated with excessive inflammation, fibrosis and vascular disease and causes hardening and restriction of the skin and internal organs such as the lungs and kidneys, sometimes progressing rapidly to death. It affects people of all ages.

It is likely that about 1,000 people in New Zealand have scleroderma with most of these patients being cared for by rheumatologists.

In 1994 the National Advisory Committee on Core Health and Disability Services considered that there should be one rheumatologist per 100,000 people. A 2004 study found that rather than improving, the provision of rheumatologists was worse with one rheumatologist per 251,211 people.

The study suggested inadequate funding and now the New Zealand Scleroderma Group calls on the Government to adequately fund rheumatological and other related services.

In 2007 a study of scleroderma patients at Middlemore Hospital in Auckland was published showing they were poorly monitored.

Although there is no cure for scleroderma, early detection and treatment of failing organs in scleroderma can improve quality and extend people’s lives.

There are monitoring programmes in centres around the world. In Australia 12 centres are involved in the Australian Scleroderma Screening Program. Three centres in New Zealand are members of a Europe based programme.

World Scleroderma Day marks the death of leading Swiss expressionist artist Paul Klee who died on this day in 1940 of scleroderma. He was diagnosed in 1935. Paul’s production slowed noticeably as scleroderma took hold. His artwork began to transform from light and joyful to murky and echoing.

The New Zealand Scleroderma Group is joining with other scleroderma groups around the world to raise awareness and improve health care for this potentially serious condition.

Source: Scoop Health (2012), "Scleroderma Patients: Call For Better Monitoring, Treatment"; Original article can be viewed here

 
More articles :

» The Many Faces of Interleukin-6: The Role of IL-6 in Inflammation, Vasculopathy, and Fibrosis in Systemic Sclerosis

Theresa C. Barnes,Marina E. Anderson, and Robert J.MootsReceived 1 June 2011; Accepted 21 July 2011Systemic sclerosis (SSc) is a connective tissue disease characterised by fibrosis, vasculopathy, and immunological abnormalities. Over recent years,...

» Long Term Methotrexate Therapy Beneficial for Juvenile Localized Scleroderma

Researchers in Italy evaluated 65 patients with Juvenile Localized (JLS; or) previously enrolled in a double blind, randomized control trial and treated for the first 3 months with oral methotrexate (MTX; 15 mg/m2 weekly) and prednisone (1 mg/kg...

» Nutrition & Dietary Supplements

A comprehensive treatment plan for may include a range of complementary and alternative therapies. Individuals with Scleroderma tend to have deficiencies in many vitamins and minerals. Ask your team of health care providers about the best ways to...

» Vascular Changes in Bleomycin-Induced Scleroderma

Toshiyuki Yamamoto and Ichiro KatayamaDepartment of Dermatology, Fukushima Medical University, Hikarigaoka 1, Fukushima 960-1295, JapanDepartment of Dermatology, Osaka University, Yamadaoka 2-2, Suita, Osaka 565-0871, JapanReceived 6 June 2011;...

» Study Reveals New Genetic Link To Scleroderma

An international research consortium including scientists from T (UTHealth) has identified a new genetic link to the systemic form of . Researchers believe a thorough understanding of the genetic nature of the disease is crucial to developing a...

» Therapies for Scleroderma-related Pulmonary Arterial Hypertension

Paul M. HassounPosted: 08/20/2009; Expert Rev Resp Med. 2009;3(2):187-196. © 2009 Expert Reviews Ltd.Pulmonary arterial hypertension (PAH), a common complication of systemic sclerosis, carries a very severe prognosis and is one of the leading...